Dermatologic complications in transplantation and cellular therapy for acute leukemia

Best Pract Res Clin Haematol. 2023 Jun;36(2):101464. doi: 10.1016/j.beha.2023.101464. Epub 2023 Apr 6.

Abstract

Adoptive cellular immunotherapy, mainly hematopoietic stem cell transplant and CAR-T cell therapy have revolutionized treatment of patients with acute leukemia. Indications and inclusion criteria for these treatments have expanded in recent years. While these therapies are associated with significant improvements in disease response and overall survival, patients may experience adverse events from associated chemotherapy conditioning, engraftment, cytokine storm, supportive medications, and post-transplant maintenance targeted therapies. Supportive oncodermatology is a growing specialty to manage cutaneous toxicities resulting from the anti-cancer therapies. In this review, we summarize diagnosis and management of the common cutaneous adverse events including drug eruptions, graft-versus-host disease, neoplastic and paraneoplastic complications in patients undergoing cellular therapies.

Keywords: CAR-T cell therapy; Dermatological complications; Drug eruptions; GVHD; Hematopoietic stem cell transplant.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Immunotherapy, Adoptive / methods
  • Leukemia, Myeloid, Acute* / therapy
  • Transplantation Conditioning / methods
  • Transplantation, Homologous / adverse effects